EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

The Use of Systemically Absorbed Drugs to Explore An In Vitro Bioequivalence Approach For Comparing Non-Systemically Absorbed Active Pharmaceutical Ingredients in Drug Products For Use in Dogs

Marilyn N Martinez, Raafat Fahmy, Linge Li, Kithsiri Herath, R Gary Hollenbeck, Ahmed Ibrahim, Stephen W Hoag, David Longstaff, Shasha Gao, Michael J Myers

Pharmaceutical Research · 2024

DOI: 10.1007/s11095-024-03766-3 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pharmaceutical Research, 2024. Verfasst von Marilyn N Martinez und 9 weiteren Autor:innen. Beteiligte Einrichtung: US Food and Drug Administration, Center for Veterinary Medicine, Office of New Animal Drugs, Rockville, MD, 20855, US. marilyn.martinez@fda.hhs.gov. Hauptthemen laut MEDLINE: Therapeutic Equivalency, Cross-Over Studies, Tablets, Ivermectin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Currently, for veterinary oral formulations containing one or more active pharmaceutical ingredient (API) that are not systemically absorbed and act locally within the gastrointestinal (GI) tract, the use of terminal clinical endpoint bioequivalence (BE) studies is the only option for evaluating product BE. This investigation explored the use of a totality of evidence approach as an alternative to these terminal studies.

Methods

Three formulations of tablets containing ivermectin plus praziquantel were manufactured to exhibit distinctly different in vitro release characteristics. Because these APIs are highly permeable, plasma drug concentrations served as a biomarker of in vivo dissolution. Tablets were administered to 27 healthy Beagle dogs (3-way crossover) and the rate and extent of exposure of each API for each formulation was compared in a pairwise manner. These results were compared to product relative in vitro dissolution profiles in 3 media. In vivo and in vitro BE predictions were compared.

Results

In vivo/in vitro inconsistencies in product relative performance were observed with both compounds when considering product performance across the 3 dissolution media. Formulation comparisons flagged major differences that could explain this outcome.

Conclusions

The finding of an inconsistent in vivo/in vitro relationship confirmed that in vitro dissolution alone cannot assure product BE for veterinary locally acting GI products. However, when combined with a comparison of product composition and manufacturing method, this totality of evidence approach can successfully alert scientists to potential therapeutic inequivalence, thereby supporting FDA’s efforts to Replace, Reduce, and/or Refine terminal animal studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Therapeutic EquivalencyCross-Over StudiesTabletsIvermectinDogsAnimalsPraziquantelSolubilityAdministration, OralMaleVeterinary DrugsChemistry, PharmaceuticalDrug LiberationFemaleBulk Drugs

Stichwörter der Autor:innen

Bioequivalence Evaluation of Non-systemically Absorbed DrugsIn Vivo/in Vitro RelationshipsIvermectinPraziquantel

Substanzen

TabletsIvermectinPraziquantelVeterinary DrugsBulk Drugs

Autor:innen und Institutionen

  • US Food and Drug Administration, Center for Veterinary Medicine, Office of New Animal Drugs, Rockville, MD, 20855, US. marilyn.martinez@fda.hhs.gov.
  • US Food and Drug Administration, Center for Veterinary Medicine, Office of New Animal Drugs, Rockville, MD, 20855, US.
  • US Food and Drug Administration, Center for Veterinary Medicine, Office of Applied Sciences, Laurel, MD, 20708, US.
  • School of Pharmacy, University Maryland Baltimore, Baltimore, MD, 21201, US.

Förderung

  • U.S. Food and Drug Administration

Zitieren

APA

Martinez, M. N., Fahmy, R., Li, L., Herath, K., Hollenbeck, R. G., Ibrahim, A., Hoag, S. W., Longstaff, D., Gao, S., & Myers, M. J. (2024). The Use of Systemically Absorbed Drugs to Explore An In Vitro Bioequivalence Approach For Comparing Non-Systemically Absorbed Active Pharmaceutical Ingredients in Drug Products For Use in Dogs. Pharmaceutical Research. https://doi.org/10.1007/s11095-024-03766-3

Vancouver

Martinez MN, Fahmy R, Li L, Herath K, Hollenbeck RG, Ibrahim A, et al. The Use of Systemically Absorbed Drugs to Explore An In Vitro Bioequivalence Approach For Comparing Non-Systemically Absorbed Active Pharmaceutical Ingredients in Drug Products For Use in Dogs. Pharmaceutical Research. 2024. doi:10.1007/s11095-024-03766-3

BibTeX
@article{Martinez2024,
  author = {Martinez, Marilyn N and Fahmy, Raafat and Li, Linge and Herath, Kithsiri and Hollenbeck, R Gary and Ibrahim, Ahmed and Hoag, Stephen W and Longstaff, David and Gao, Shasha and Myers, Michael J},
  title = {The Use of Systemically Absorbed Drugs to Explore An In Vitro Bioequivalence Approach For Comparing Non-Systemically Absorbed Active Pharmaceutical Ingredients in Drug Products For Use in Dogs},
  journal = {Pharmaceutical Research},
  year = {2024},
  doi = {10.1007/s11095-024-03766-3}
}
Kostenlos starten →